On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

A new study reveals "serious adverse events" associated with mifepristone, commonly called the "abortion pill," as ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from ...

WE NEED TO TAKE A LOOK AT THE LABELS WHERE WE CAN AND TRY TO ... according to the FDA, whose decision approves a 2023 petition filed by New Jersey-based Innophos Inc., a mineral solutions company.

This should serve as an urgent safety signal for the FDA and is more consistent with what I see in clinical practice,” said ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

No use of the drug has received FDA approval as it can result in serious ... is prescribed and dispensed or revised the drug label to warn of possible addiction," Makary said.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...